EHA 2018 Annual Congress Highlights in Multiple Myeloma

EHA 2018 Annual Congress Highlights in Multiple Myeloma
EHA 2018 Annual Congress Highlights in Multiple Myeloma
CME, CPE, CNE
María-Victoria Mateos, MD, PhD; Paul G. Richardson, MD; Joshua Richter, MD; and Saad Z. Usmani, MD, FACP
Release Date: August 22, 2018
Expiration Date: August 22, 2019

In this activity, key opinion leaders present important highlights of several significant scientific updates in multiple myeloma (MM) presented at the 2018 European Hematology Association (EHA) Annual Meeting. You can view videos from the meeting and listen as they share insights on a variety of abstracts covering topics including, but not limited to: three- versus two-drug regimens; optimizing carfilzomib-based chemotherapy regimens; new anti-CD38 monoclonal antibodies; a new wave of oral therapies for MM; and the importance of minimal residual disease testing among patients with newly diagnosed and relapsed/refractory MM.

This activity provides notable highlights from several important clinical trials including OPTIMISMM, A.R.R.O.W., and INSIGHT MM, among others, as well as data on venetoclax, a BCL-2 inhibitor, as treatment for relapsed/refractory disease. Take advantage of this excellent opportunity to see how the future of treatment in myeloma is continuing to evolve and how these changes may improve outcomes for your patients.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
Begin, Earn CreditView Only, No CreditGet Certificate